Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  American Journal of Physiology. Endocrinology and Metabolism

• Publication date

  2008-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1152/ajpendo.00030.2008PMID 18334612
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Exenatide

  2012cited by this paper
• Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus

  2006influential reference
• Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans

  2006cited by this paper
• Postprandial lipaemia induces an acute decrease of insulin sensitivity in healthy men independently of plasma NEFA levels

  2006cited by this paper
• GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats.

  2005cited by this paper
• Pharmacokinetics of an Oral Drug (Acetaminophen) Administered at Various Times in Relation to Subcutaneous Injection of Exenatide (Exendin‐4) in Healthy Subjects

  2005cited by this paper
• A Quantitative Study

  2005cited by this paper
• Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers.

  2001cited by this paper
• Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor.

  2001cited by this paper
• Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.

  2001cited by this paper
• Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes.

  2000cited by this paper
• Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration.

  2000cited by this paper
• Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations

  1999cited by this paper
• Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo.

  1999cited by this paper
• Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

  1999cited by this paper
• Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

  1998cited by this paper
• Evidence for decreased splanchnic glucose uptake after oral glucose administration in non-insulin-dependent diabetes mellitus.

  1997cited by this paper
• Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.

  1997influential reference
• PATHOGENESIS OF TYPE 2 DIABETES: METABOLIC AND MOLECULAR IMPLICATIONS FOR IDENTIFYING DIABETES GENES

  1997cited by this paper
• Enteroglucagon.

  1997cited by this paper
• Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

  1996cited by this paper
• Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal.

  1994cited by this paper
• Enteroglucagon

  1994cited by this paper
• Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.

  1993influential reference
• Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state.

  1992influential reference
• Insulinotropic Action of Glucagonlike Peptide-I-(7–37) in Diabetic and Nondiabetic Subjects

  1992influential reference
• Contribution of Abnormal Muscle and Liver Glucose Metabolism to Postprandial Hyperglycemia in NIDDM

  1990cited by this paper
• Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM.

  1990cited by this paper
• Effects of Basal Insulin Supplementation on Disposition of Mixed Meal in Obese Patients With NIDDM

  1989cited by this paper
• The disposal of an oral glucose load in patients with non-insulin-dependent diabetes.

  1988cited by this paper
• ON THINGS HEARD

  1985cited by this paper
• The Disposal of an Oral Glucose Load in Healthy Subjects: A Quantitative Study

  1985cited by this paper
• Splanchnic and Peripheral Disposal of Oral Glucose in Man

  1983cited by this paper
• Influence of hyperinsulinemia, hyperglycemia, and the route of glucose administration on splanchnic glucose exchange.

  1978cited by this paper
• Drugs

  1967cited by this paper
• The surprising simplicity of sensory metrics.

  1962cited by this paper
• Voice Level: Autophonic Scale, Perceived Loudness, and Effects of Sidetone

  1961cited by this paper
• Auditory irritants and impalpable pain.

  1959cited by this paper

• Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement.

  2025cites this paper
• Endoscopy and Anesthesia Outcomes Associated with Glucagon-Like Peptide-1 Receptor Agonist use in Patients Undergoing Outpatient Upper Endoscopy.

  2025cites this paper
• Unlocking the Potential of Pyrrolidine Derivatives as Antidiabetic Agents: Insights from Physicochemical Analysis, Molecular Docking, ADMET, and DFT Studies

  2025cites this paper
• Partial AUCs in Long-Acting Injectables: Rationale, Challenges, Variability, Usefulness, and Clinical Relevance

  2024cites this paper
• Overview of Sleeve Gastrectomy and Roux-en-Y Bypass for Gastroparesis

  2024cites this paper
• Is it necessary to stop glucagon-like peptide-1 receptor agonists prior to endoscopic procedure? A retrospective study

  2024cites this paper
• Perioperative Management of Patients Taking Glucagon-like Peptide-1 Receptor Agonists: Applying Evidence to Clinical Practice

  2024cites this paper
• Prandial Insulins: A Person-Centered Choice

  2024cites this paper
• Perfecting the Puzzle of Pathophysiology: Exploring Combination Therapy in the Treatment of Type 2 Diabetes

  2023cites this paper
• Gastroparesis: an evidence-based review for the bariatric and foregut surgeon.

  2023cites this paper
• Emergence of a New Gluco-Regulatory Mechanism for Glycemic Control with Dapagliflozin/Exenatide Therapy in Type 2 Diabetes.

  2023cites this paper
• Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose.

  2022cites this paper
• Bolus Injection of Liraglutide Raises Plasma Glucose in Normal Rats by Activating Glucagon-like Peptide 1 Receptor in the Brain

  2022cites this paper
• Role of Glucagon-like Peptide-1 (GLP-1) Agonists in the Management of Diabetic Patients with or without COVID-19

  2022cites this paper
• Potential role of IGF-1/GLP-1 signaling activation in intracerebral hemorrhage

  2022cites this paper
• Comparative effects of incretin-based therapy on early-onset diabetic nephropathy in rats: Role of TNF-α, TGF-β and c-caspase-3.

  2021cites this paper
• Synthesis, in vitro and in silico enzymatic inhibition assays, and toxicity evaluations of new 4,5-diphenylimidazole-N-phenylacetamide derivatives as potent α-glucosidase inhibitors

  2021cites this paper
• Glucagon-Like Peptide-1 Receptor Agonist Effects on Gastric Motility: A Systematic Review

  2020cites this paper
• Pathophysiology, Aetiology and Treatment of Gastroparesis

  2020cites this paper
• Acute Exenatide Therapy Attenuates Postprandial Vasodilation in Humans with Prediabetes: A Randomized Controlled Trial

  2020influential citation
• Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity.

  2020cites this paper
• A Systematic Review On Synthetic Drugs And Phytopharmaceuticals Used To Manage Diabetes.

  2019cites this paper
• Insulin Resistance and Atherosclerosis: Implications for Insulin Sensitizing Agents.

  2019cites this paper
• Prédiction à long terme de la rémission et de la rechute du diabète de type 2 après bypass Roux-en-Y : développement et validation d’un score prédictif, le 5y-Ad-DiaRem

  2019cites this paper
• DIABETIC GASTROPARESIS.

  2019cites this paper
• The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia

  2019cites this paper
• Exendin‐4 from Heloderma suspectum venom: From discovery to its latest application as type II diabetes combatant

  2018cites this paper
• A vitamin B12 conjugate of exendin‐4 improves glucose tolerance without associated nausea or hypophagia in rodents

  2018cites this paper
• Type 2 Diabetes Mellitus. From the start – combination therapy

  2018cites this paper
• Agonistas de GLP-1 más inhibidores de SGLT2. ¿Efectos cardioprotectores aditivos?

  2018cites this paper
• Prevention and Treatment of Type 2 Diabetes: A Pathophysiological-Based Approach.

  2018cites this paper
• Treatment with GLP-1 Receptor Agonists

  2018cites this paper
• The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes

  2018cites this paper
• Glucose lowering and vascular protective effects of cycloset added to GLP‐1 receptor agonists in patients with type 2 diabetes

  2018cites this paper
• Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study)

  2017cites this paper
• Gene expression signature: a powerful approach for drug discovery in diabetes.

  2017cites this paper
• Combination therapy with GLP‐1 receptor agonist and SGLT2 inhibitor

  2017cites this paper
• Improving glycemic control in type 2 diabetes : stimulate insulin secretion or provide beta-cell rest ?

  2017cites this paper
• Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes.

  2017cites this paper
• Model‐Based Evaluation of Exenatide Effects on the QT Interval in Healthy Subjects Following Continuous IV Infusion

  2017cites this paper
• Using abrupt change detection to categorize glucose variability of Type 1 diabetes patients

  2017cites this paper
• Decreased basal hepatic glucose uptake in impaired fasting glucose

  2017cites this paper
• Use of glucagon-like peptide-1 agonists in treatment of morphologicalmanifestations of diabetic gastroparesis

  2017cites this paper
• Improving glycaemic control in type 2 diabetes: Stimulate insulin secretion or provide beta‐cell rest?

  2017cites this paper
• Optimisation du contrôle glycémique en chirurgie cardiaque : variabilité glycémique, compliance aux protocoles de soins, et place des incrétino-mimétiques

  2017cites this paper
• Évaluation de la fonction β cellulaire par le repas-test chez le diabétique de type 2 : intérêt clinique

  2017cites this paper
• Gastrointestinal and Cardiovascular Effects of Incretin-Based Therapies: Friend or Foe?

  2017cites this paper
• The Management of Obesity: An Overview

  2017cites this paper
• Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß‐cell function in non‐diabetic, morbidly obese patients

  2017influential citation
• Understanding the Etiology and Spectrum of Idiopathic Gastroparesis

  2017cites this paper
• Clinical Effectiveness of Intravenous Exenatide Infusion in Perioperative Glycemic Control after Coronary Artery Bypass Graft Surgery: A Phase II/III Randomized Trial

  2017cites this paper
• Non‐insulin anti‐diabetic drugs: An update on pharmacological interactions

  2017cites this paper
• Exenatide improves β-cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial.

  2016cites this paper
• Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study

  2016cites this paper
• Differential effects of once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide and metformin on pancreatic β‐cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes

  2016cites this paper
• Postprandial dysmetabolism: Too early or too late?

  2016cites this paper
• Biochemical Efficacy of Various Anti-Diabetic Drugs on A Combination of High Fat Diet Fed And Low Dose of Streptozotocin Treated Rats As A Model for Type 2 Diabetes

  2016cites this paper
• Cardiovascular Effects of the New Weight Loss Agents.

  2016cites this paper
• Discordance Between Central (Brain) and Pancreatic Action of Exenatide in Lean and Obese Subjects

  2016cites this paper
• GLP‐1 analogue use in patients with sub‐optimally controlled type 1 diabetes or obesity improves weight and HbA1c

  2016cites this paper
• Gastrointestinal actions of glucagon‐like peptide‐1‐based therapies: glycaemic control beyond the pancreas

  2016cites this paper
• Incretins.

  2016cites this paper
• Population pharmacokinetics of exenatide

  2016cites this paper
• Bariatric surgery and type 2 diabetes: are there weight loss‐independent therapeutic effects of upper gastrointestinal bypass?

  2016cites this paper
• Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk

  2016cites this paper
• Rôle du glucagon dans la physiopathologie et le traitement du diabète

  2016cites this paper
• Delivery of Exenatide and Insulin Using Mucoadhesive Intestinal Devices

  2016cites this paper
• Gastrointestinal traits: individualizing therapy for obesity with drugs and devices.

  2016cites this paper
• Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm

  2016cites this paper
• Combination therapy of SGLT2 inhibitors with incretin-based therapies for the treatment of type 2 diabetes mellitus: Effects and mechanisms of action

  2016cites this paper
• Inter-regulation of gastric emptying and incretin hormone secretion: implications for postprandial glycemic control.

  2016cites this paper
• The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism

  2016cites this paper
• Lixisenatide accelerates restoration of normoglycemia and improves human beta-cell function and survival in diabetic immunodeficient NOD–scid IL-2rgnull RIP-DTR mice engrafted with human islets

  2015cites this paper
• Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study

  2015cites this paper
• Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans

  2015cites this paper
• Type 2 diabetes mellitus

  2015cites this paper
• THE RATIONALE FOR USE OF INCRETINS IN THE MANAGEMENT OF NEW ONSET DIABETES AFTER TRANSPLANTATION (NODAT).

  2015cites this paper
• Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes

  2015cites this paper
• Practical implementation of incretin-based therapy in hospitalized patients with type 2 diabetes

  2015cites this paper
• Combination therapy in type 2 diabetes mellitus

  2015cites this paper
• lixisenatide accelerates restoration of normoglycemia and improves human beta-cell function and survival in diabetic immunodeficient

  2015cites this paper
• Metformin decreases glycated albumin to glycated haemoglobin ratio in patients with newly diagnosed type 2 diabetes

  2015cites this paper
• MESA 1: NUEVOS MEDICAMENTOS EN DIABETES MELLITUS TIPO 1

  2015cites this paper
• Effects of metformin on weight loss: potential mechanisms

  2014cites this paper
• Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making

  2014cites this paper
• Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes.

  2014cites this paper
• A randomized, double-blind, placebo-controlled, multiple-dose, parallel-group clinical trial to assess the effects of teduglutide on gastric emptying of liquids in healthy subjects

  2014cites this paper
• Pathophysiological and Pharmacological Rationale for the Use of Exenatide Once Weekly in Patients with Type 2 Diabetes

  2014cites this paper
• Assessment of Pancreatic β-Cell Function: Review of Methods and Clinical Applications

  2014cites this paper
• Steroid diabetes: from mechanism to treatment?

  2014cites this paper
• The effect of chronic twice daily exenatide treatment on β‐cell function in new onset type 2 diabetes

  2014cites this paper
• Meal feeding improves oral glucose tolerance in male rats and causes adaptations in postprandial islet hormone secretion that are independent of plasma incretins or glycemia.

  2014cites this paper
• Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents

  2014cites this paper
• Characterization of the exocrine pancreas in the male Zucker diabetic fatty rat model of type 2 diabetes mellitus following 3 months of treatment with sitagliptin.

  2014cites this paper
• Can GLP-1 preparations be used in children and adolescents with diabetes mellitus?

  2014cites this paper
• PRECLINOMICS: ENZYME ASSAYS AND RODENT MODELS FOR METABOLIC DISEASES

  2014cites this paper
• A direct comparison of long‐ and short‐acting GLP‐1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment

  2014cites this paper
• Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.

  2014cites this paper
• Lixisenatide as add-on therapy to basal insulin

  2013cites this paper
• Rapid Improvement in Diabetes After Gastric Bypass Surgery

  2013cites this paper